Literature DB >> 11726971

HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.

J Martin-Serrano1, T Zang, P D Bieniasz.   

Abstract

Retroviral Gag proteins encode sequences, termed late domains, which facilitate the final stages of particle budding from the plasma membrane. We report here that interactions between Tsg101, a factor involved in endosomal protein sorting, and short peptide motifs in the HIV-1 Gag late domain and Ebola virus matrix (EbVp40) proteins are essential for efficient egress of HIV-1 virions and Ebola virus-like particles. EbVp40 recruits Tsg101 to sites of particle assembly and a short, EbVp40-derived Tsg101-binding peptide sequence can functionally substitute for the HIV-1 Gag late domain. Notably, recruitment of Tsg101 to assembling virions restores budding competence to a late-domain-defective HIV-1 in the complete absence of viral late domain. These studies define an essential virus-host interaction that is conserved in two unrelated viruses. Because the Tsg101 is recruited by small, conserved viral sequence motifs, agents that mimic these structures are potential inhibitors of the replication of these lethal human pathogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726971     DOI: 10.1038/nm1201-1313

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  370 in total

1.  Structure and functional interactions of the Tsg101 UEV domain.

Authors:  Owen Pornillos; Steven L Alam; Rebecca L Rich; David G Myszka; Darrell R Davis; Wesley I Sundquist
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 2.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Role of ESCRT-I in retroviral budding.

Authors:  Juan Martin-Serrano; Trinity Zang; Paul D Bieniasz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through targeting endosomal sorting complex required for transport-I.

Authors:  Qi Da; Xuanming Yang; Youli Xu; Guangxia Gao; Genhong Cheng; Hong Tang
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

Review 5.  Proline-rich regions and motifs in trafficking: from ESCRT interaction to viral exploitation.

Authors:  Xuefeng Ren; James H Hurley
Journal:  Traffic       Date:  2011-05-13       Impact factor: 6.215

6.  Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Authors:  Natallia Dziuba; Monique R Ferguson; William A O'Brien; Anthony Sanchez; Andrew J Prussia; Natalie J McDonald; Brian M Friedrich; Guangyu Li; Michael W Shaw; Jinsong Sheng; Thomas W Hodge; Donald H Rubin; James L Murray
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

7.  The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies.

Authors:  Mar Perez; Rebecca C Craven; Juan C de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

8.  Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding.

Authors:  Ziying Han; Hani Boshra; J Oriol Sunyer; Susan H Zwiers; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  The membrane trafficking protein calpactin forms a complex with bluetongue virus protein NS3 and mediates virus release.

Authors:  Andrew R Beaton; Javier Rodriguez; Y Krishnamohan Reddy; Polly Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

10.  Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins.

Authors:  Juan Martin-Serrano; Anton Yarovoy; David Perez-Caballero; Paul D Bieniasz; Anton Yaravoy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.